Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
dangers decrease » larger decrease (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
dangers decrease » larger decrease (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
-
1981
Verification of PLUS CYCLE<sup>®</sup> signals during presumed sleep periods.
Published 2025Subjects: -
1982
-
1983
-
1984
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
1985
-
1986
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
1987
-
1988
-
1989
-
1990
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
1991
-
1992
-
1993
-
1994
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
1995
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
1996
-
1997
-
1998
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
1999
-
2000